Clinical trial · Observational
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Merkel Cell Carcinoma of Skin
NCT06780475CI-TRIAL-00097523VIRASKINrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to test and validate in vitro a cell therapy approach for MCPyV+ Merkel Cell Carcinoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Merkel Cell Carcinoma of Skin | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Anti-MCPyV functionality
- timeFrame
- Day 0 and Day 4
- description
- Anti-MCPyV functionality, including cytotoxicity, of T cells obtained after in vitro culture.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \>= 18 years old; * Diagnosed with Merkel cell carcinoma of skin, ongoing for local treatment, systemic treatment, complementary treatment or an active follow-up; * Informed for the study and no-opposed for participation; * Affiliated with a social security scheme or in an equivalent situation. Exclusion Criteria: * Patients ongoing another interventional clinical trial; * Patients under guardianship or trusteeship; * Pregnancy or breastfeed; * Patients refusal.
References
Publications (0)
Data not yet available
No reference posted for this study.